Become A Client
Sign in: Client Portal

About
Solutions
Coverage
Insights
- Free Analyst Insights
- Signify Premium Insights
News & Events
Careers
- Vacancies
Contact
- Contact Us
- Ask An Analyst

About
Solutions
Coverage
Insights
- Free Analyst Insights
- Signify Premium Insights
News & Events
Careers
- Vacancies
Contact
- Contact Us
- Ask An Analyst

Become A Client
Sign in: Client Portal

Medical Imaging

AI in Medical Imaging
Breast Imaging
Diagnostic Imaging Procedure Volumes
Imaging IT
Medical Imaging Yearbook
Teleradiology
X-Ray
Signify Premium Insights

Clinical Care

Anaesthesia Devices
Ambulatory Diagnostic Cardiology
Diagnostic Cardiology
Fetal Monitors
High-Acuity Clinical Information Systems
Infusion Pumps
Patient Monitor Consumables
Remote Patient Monitoring

Digital Health

Electronic Medical Records
Generative AI
Patient Engagement
Telehealth
Signify Premium Insights

Diagnostics and Lifesciences

AI in Drug Development & Clinical Trials
Digital Pathology
Oncology IT
Real-World Data – A Strategic Analysis

Healthcare IT

Digital Pathology
High-Acuity Clinical Information Systems
Oncology IT

Ai in Healthcare

AI in Diagnostic Cardiology ECG
AI in Medical Imaging Service
Generative AI Service
Ultrasound AI
Signify Premium Insights

Three Reasons why Growth in the Mammography Market Will Slow

Share:

Share on Linkedin

Imogen Fitt

Published: August 2, 2019 In The News

2nd August 2019 – Written by Imogen Fitt – Featured in AuntMinnie.com – When breast imaging comes to mind, mammography is the undisputed current modality of choice. Other breast imaging modalities, such as MRI and ultrasound, form a comparatively smaller part of the market. For this reason, it is mammography that has typically driven the majority of market growth in breast imaging.

Read full article here

You may also like

18 Feb 2021: Diagnostics and Lifesciences, Digital Health, Healthcare IT

Are EMR-based Oncology Modules Threatening Best-of-Breed Oncology IT?

The healthcare IT landscape is moving towards closely integrated software, often based on EMR platforms. Many clinical departments have traditionally run independent information systems, such as Radiology Information Systems (RIS) and Cardiovascular Information Systems (CVIS), but as the adoption of Electronic Medical Records (EMRs) has gained momentum, we have seen increasing cannibalisation of these departmental solutions by EMR-based clinical modules.

12 Jan 2023: Diagnostics and Lifesciences

Develop, Partner, Acquire or Avoid – Where’s Investment for Digital Pathology Headed?

Imogen Fitt of Signify Research attended the 9th Digital Pathology and AI Congress: Europe in December. In the article below she shares her thoughts on the conference with respect to recent industry discourse.

25 Feb 2021: AI in Healthcare, Diagnostics and Lifesciences

AI in Drug Development & Clinical Trials Market to Reach $3.0 Billion by 2024

The world market for AI used in drug development and clinical trials is set to reach almost $3.0 billion by 2024.

Get in touch

Please complete the form to the right for enquiries relating to sales, vendor briefings or for media interviews with our analysts or use one of the contact details below.

enquiries@signifyresearch.net

+44 1234 986111

Cranfield Innovation Centre
University Way
Cranfield
MK43 0BT
United Kingdom

Can we help?

© 2024 All rights reserved.

Contact
Help & Support
Website Privacy Policy